TALEN

TALEN1-scg2b

ID

ZDB-TALEN-190311-2

Name

TALEN1-scg2b

Previous Names

None

Target

scg2b (1)

Target Sequence 1

5' - TCCCAGCTCCGATATGA - 3'

Target Sequence 2

5' - TGCTTTAAGCTTTCGAT - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
ihb603	scg2b
ihb604	scg2b

Expression

Gene expression in Wild Types + TALEN1-scg2b

No data available

Phenotype

Phenotype resulting from TALEN1-scg2b

No data available

Phenotype of all Fish created by or utilizing TALEN1-scg2b

Phenotype	Fish	Conditions	Figures
whole organism MAPK cascade occurrence, ameliorated	scg2b^{ihb603/ihb603} (AB)	chemical treatment by environment: N-arachidonoyl-L-serine	Fig. 6 from Tao et al., 2018
whole organism phosphatidylinositol 3-kinase/protein kinase B signal transduction decreased occurrence, abnormal	scg2b^{ihb603/ihb603} (AB)	standard conditions	Fig. 5, Fig. 6 from Tao et al., 2018
hypophysis scg2a expression increased amount, abnormal	scg2b^{ihb603/ihb603} (AB)	standard conditions	Fig. 2 from Tao et al., 2018
brain MAPK cascade decreased occurrence, abnormal	scg2b^{ihb603/ihb603} (AB)	standard conditions	Fig. 5 from Tao et al., 2018
whole organism phosphatidylinositol 3-kinase/protein kinase B signal transduction occurrence, ameliorated	scg2b^{ihb603/ihb603} (AB)	chemical treatment by environment: N-arachidonoyl-L-serine	Fig. 6 from Tao et al., 2018
brain scg2b expression decreased amount, abnormal	scg2b^{ihb603/ihb603} (AB)	standard conditions	Fig. 2 from Tao et al., 2018
central artery MAPK cascade decreased occurrence, abnormal	scg2b^{ihb603/ihb603} (AB)	standard conditions	Fig. 5 from Tao et al., 2018
whole organism MAPK cascade decreased occurrence, abnormal	scg2b^{ihb603/ihb603} (AB)	control	Fig. 6 from Tao et al., 2018
central artery blood vessel morphogenesis occurrence, ameliorated	scg2b^{ihb603/ihb603}; s843Tg (AB)	chemical treatment by environment: N-arachidonoyl-L-serine	Fig. 6 from Tao et al., 2018
central artery angiogenesis decreased occurrence, abnormal	scg2b^{ihb603/ihb603}; s843Tg (AB)	standard conditions	Fig. 2 from Tao et al., 2018
central artery blood vessel morphogenesis decreased occurrence, abnormal	scg2b^{ihb603/ihb603}; s843Tg (AB)	control	Fig. 6 from Tao et al., 2018
hindbrain central artery malformed, abnormal	scg2b^{ihb603/ihb603}; s843Tg (AB)	standard conditions	Fig. 2, Fig. 6 from Tao et al., 2018
central artery vasculature development decreased occurrence, abnormal	scg2b^{ihb603/ihb603}; s843Tg (AB)	standard conditions	Fig. 2 from Tao et al., 2018
hindbrain central artery morphology, ameliorated	scg2b^{ihb603/ihb603}; s843Tg (AB)	chemical treatment by environment: N-arachidonoyl-L-serine	Fig. 6 from Tao et al., 2018
central artery MAPK cascade decreased occurrence, abnormal	scg2b^{ihb603/ihb603}; s843Tg (AB)	standard conditions	Fig. 5 from Tao et al., 2018
central artery blood vessel endothelial cell migration decreased rate, abnormal	scg2b^{ihb603/ihb603}; s843Tg (AB)	standard conditions	Fig. 4 from Tao et al., 2018
central artery vascular endothelial cell proliferation decreased occurrence, abnormal	scg2b^{ihb603/ihb603}; s843Tg (AB)	standard conditions	Fig. 4 from Tao et al., 2018
hypophysis scg2a expression absent, abnormal	scg2a^{ihb601/ihb601}; scg2b^{ihb603/ihb603} (AB)	standard conditions	Fig. 2 from Tao et al., 2018
central artery angiogenesis decreased occurrence, abnormal	scg2a^{ihb601/ihb601}; scg2b^{ihb603/ihb603}; s843Tg (AB)	standard conditions	Fig. 2 from Tao et al., 2018
hindbrain central artery malformed, abnormal	scg2a^{ihb601/ihb601}; scg2b^{ihb603/ihb603}; s843Tg (AB)	standard conditions	Fig. 2 from Tao et al., 2018
central artery vasculature development decreased occurrence, abnormal	scg2a^{ihb601/ihb601}; scg2b^{ihb603/ihb603}; s843Tg (AB)	standard conditions	Fig. 2 from Tao et al., 2018

Citations